Background: Sars-Cov-2 epidemic in Italy caused one of the greatest 2020 European outbreaks, with suspension of elective bariatric/metabolic surgery (BMS). From May 2020 a significant decline of the epidemic has been observed (phase 2); National Health Service protocols permitted elective BMS' resumption. A new, more severe COVID-19 surge, the "second wave", started on October 2020 (phase 3). Aim: The primary end point was to analyze the outcomes of any Sars-Cov-2 infection and related morbidity/mortality within 30 POD after laparoscopic BMS during phase 2-3; secondary end points were readmission and reoperation rates. Methods: Study design prospective, multicenter, observational. Setting: Eight Italian high-volume bariatric centers. All patients undergoing BMS from July 2020 through January 2021 were enrolled according to the following criteria: no Sars-Cov-2 infection; primary procedures; no concomitant procedure; age > 18 < 60 years; compensated comorbidities; informed consent including COVID-19 addendum; adherence to specific admission, in-hospital and follow-up protocols. Data were collected in a prospective database. Patients undergone BMS during July-December 2019 were considered a control group. Results: 1258 patients were enrolled and compared with 1451 operated on in 2019, with no differences for demographics, complications, readmission, and reintervention rates. Eight patients (0·6%) tested positive for Sars-Cov-2 infection after discharge, as well as and 15 healthcare professionals, with no related complications or mortality. Conclusions: Introduction of strict COVID-19 protocols concerning the protection of patients and health-care professionals guaranteed a safe resumption of elective BMS in Italy. The safety profile was, also, maintained during the second wave of outbreak, thus allowing access to a cure for the obese population.

Laparoscopic bariatric surgery is safe during phase 2-3 of COVID-19 pandemic in Italy. A multicenter, prospective, observational study / Silecchia, Gianfranco; Boru, Cristian Eugeniu; M Marinari, Giuseppe; Gentileschi, Paolo; Morino, Mario; Olmi, Stefano; Foletto, Mirto; Bernante, Paolo; Morganti, Riccardo; Tascini, Carlo; Anselmino, Marco; Bianciardi, Emanuela; Campanelli, Michela; Fiorello, Luigi; Mancini, Rudj; Oldani, Alberto; Rottoli, Matteo; Salzano, Antonio; Trotta, Manuela. - In: DIABETES RESEARCH AND CLINICAL PRACTICE. - ISSN 0168-8227. - 177:(2021). [10.1016/j.diabres.2021.108919]

Laparoscopic bariatric surgery is safe during phase 2-3 of COVID-19 pandemic in Italy. A multicenter, prospective, observational study

Silecchia, Gianfranco
Primo
Conceptualization
;
Boru, Cristian Eugeniu
Secondo
Project Administration
;
Bianciardi, Emanuela
Membro del Collaboration Group
;
Salzano, Antonio
Membro del Collaboration Group
;
2021

Abstract

Background: Sars-Cov-2 epidemic in Italy caused one of the greatest 2020 European outbreaks, with suspension of elective bariatric/metabolic surgery (BMS). From May 2020 a significant decline of the epidemic has been observed (phase 2); National Health Service protocols permitted elective BMS' resumption. A new, more severe COVID-19 surge, the "second wave", started on October 2020 (phase 3). Aim: The primary end point was to analyze the outcomes of any Sars-Cov-2 infection and related morbidity/mortality within 30 POD after laparoscopic BMS during phase 2-3; secondary end points were readmission and reoperation rates. Methods: Study design prospective, multicenter, observational. Setting: Eight Italian high-volume bariatric centers. All patients undergoing BMS from July 2020 through January 2021 were enrolled according to the following criteria: no Sars-Cov-2 infection; primary procedures; no concomitant procedure; age > 18 < 60 years; compensated comorbidities; informed consent including COVID-19 addendum; adherence to specific admission, in-hospital and follow-up protocols. Data were collected in a prospective database. Patients undergone BMS during July-December 2019 were considered a control group. Results: 1258 patients were enrolled and compared with 1451 operated on in 2019, with no differences for demographics, complications, readmission, and reintervention rates. Eight patients (0·6%) tested positive for Sars-Cov-2 infection after discharge, as well as and 15 healthcare professionals, with no related complications or mortality. Conclusions: Introduction of strict COVID-19 protocols concerning the protection of patients and health-care professionals guaranteed a safe resumption of elective BMS in Italy. The safety profile was, also, maintained during the second wave of outbreak, thus allowing access to a cure for the obese population.
2021
bariatric/metabolic surgery; guidelines; phase 2·3 COVID-19 pandemic; protocols; safety; Sars-Cov-2 infection
01 Pubblicazione su rivista::01a Articolo in rivista
Laparoscopic bariatric surgery is safe during phase 2-3 of COVID-19 pandemic in Italy. A multicenter, prospective, observational study / Silecchia, Gianfranco; Boru, Cristian Eugeniu; M Marinari, Giuseppe; Gentileschi, Paolo; Morino, Mario; Olmi, Stefano; Foletto, Mirto; Bernante, Paolo; Morganti, Riccardo; Tascini, Carlo; Anselmino, Marco; Bianciardi, Emanuela; Campanelli, Michela; Fiorello, Luigi; Mancini, Rudj; Oldani, Alberto; Rottoli, Matteo; Salzano, Antonio; Trotta, Manuela. - In: DIABETES RESEARCH AND CLINICAL PRACTICE. - ISSN 0168-8227. - 177:(2021). [10.1016/j.diabres.2021.108919]
File allegati a questo prodotto
File Dimensione Formato  
Silecchia_Laparoscopic_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 418.75 kB
Formato Adobe PDF
418.75 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1562365
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact